Janus Henderson Group PLC Acquires 10,664 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Janus Henderson Group PLC raised its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 7.8% in the first quarter, Holdings Channel reports. The fund owned 147,089 shares of the biopharmaceutical company’s stock after purchasing an additional 10,664 shares during the quarter. Janus Henderson Group PLC’s holdings in Alnylam Pharmaceuticals were worth $48,661,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. MV Capital Management Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $25,000. HM Payson & Co. acquired a new position in Alnylam Pharmaceuticals in the fourth quarter valued at $27,000. Golden State Wealth Management LLC boosted its position in Alnylam Pharmaceuticals by 100.0% during the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 36 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Alnylam Pharmaceuticals during the third quarter valued at $29,000. Finally, Manchester Capital Management LLC grew its holdings in Alnylam Pharmaceuticals by 600.0% during the 4th quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 72 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Key Headlines Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Chardan Capital reaffirmed its Buy rating and assigned a $425 price target, while JPMorgan, RBC, Oppenheimer, and Stifel maintained bullish ratings despite lowering their targets. The revised targets remain well above the current trading level. Analyst ratings and price targets
• Positive Sentiment: Alnylam reported continued strength in its transthyretin franchise, including record quarterly Amvuttra sales, and revenue increased substantially from the prior-year period. These results support the company’s underlying commercial momentum. Alnylam Q2 2026 earnings call
• Neutral Sentiment: Analysts broadly lowered their targets: JPMorgan cut its target to $375, RBC to $350, Oppenheimer to $350, Stifel to $318, Wells Fargo to $316, and Morgan Stanley to $300. Ratings range from Buy/Outperform to Equal Weight, indicating optimism about valuation but greater near-term uncertainty. Analyst price-target changes
• Negative Sentiment: Second-quarter adjusted earnings of $1.84 per share exceeded some consensus measures but missed the $2.05 Zacks estimate, while revenue of $1.29 billion fell short of the roughly $1.32 billion consensus. Alnylam Q2 earnings miss
• Negative Sentiment: The company cut its 2026 product-revenue outlook to $5.3 billion-$5.7 billion, reflecting normalization in second-line Amvuttra demand and headwinds affecting the ATTR-CM market. The guidance reduction is the primary catalyst behind the stock’s decline. Alnylam lowers 2026 outlook
• Negative Sentiment: Several law firms announced securities-fraud investigations following the results and guidance cut. These announcements may add reputational and legal overhang, although they do not establish wrongdoing. Securities-fraud investigation

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the sale, the director directly owned 1,582 shares of the company’s stock, valued at $473,302.76. This trade represents a 70.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.86% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on ALNY shares. Weiss Ratings raised Alnylam Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday. Wells Fargo & Company lowered their target price on Alnylam Pharmaceuticals from $377.00 to $316.00 and set an “equal weight” rating for the company in a report on Friday. Morgan Stanley dropped their price target on Alnylam Pharmaceuticals from $400.00 to $300.00 and set an “equal weight” rating on the stock in a research note on Friday. Truist Financial reduced their price objective on shares of Alnylam Pharmaceuticals from $505.00 to $410.00 and set a “buy” rating for the company in a research report on Monday, July 13th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Alnylam Pharmaceuticals from $400.00 to $375.00 and set an “overweight” rating on the stock in a research report on Friday. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $410.72.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $205.52 on Friday. The company has a market cap of $27.44 billion, a P/E ratio of 38.20 and a beta of 0.27. The company has a fifty day simple moving average of $287.96 and a 200 day simple moving average of $311.32. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94. Alnylam Pharmaceuticals, Inc. has a 12-month low of $197.81 and a 12-month high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, beating analysts’ consensus estimates of $0.87 by $1.12. The firm had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 104.81%. The business’s quarterly revenue was up 96.4% compared to the same quarter last year. During the same period last year, the firm earned ($0.44) earnings per share. Sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post 7.22 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.